1. Home
  2. FGNX vs BYSI Comparison

FGNX vs BYSI Comparison

Compare FGNX & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FGNX

Fundamental Global Inc.

HOLD

Current Price

$7.54

Market Cap

44.1M

Sector

Finance

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

HOLD

Current Price

$0.71

Market Cap

35.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGNX
BYSI
Founded
1932
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.1M
35.8M
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
FGNX
BYSI
Price
$7.54
$0.71
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$35.00
N/A
AVG Volume (30 Days)
107.2K
2.0M
Earning Date
05-19-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$32,023,000.00
N/A
Revenue This Year
$650.31
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
20.70
N/A
52 Week Low
$1.59
$0.67
52 Week High
$15.10
$2.44

Technical Indicators

Market Signals
Indicator
FGNX
BYSI
Relative Strength Index (RSI) 55.94 30.83
Support Level $5.64 N/A
Resistance Level $7.71 $1.30
Average True Range (ATR) 0.76 0.11
MACD -0.05 0.00
Stochastic Oscillator 63.89 5.87

Price Performance

Historical Comparison
FGNX
BYSI

About FGNX Fundamental Global Inc.

FG Nexus Inc operates through two primary segments: Digital Assets and Merchant Banking, with Digital Assets contributing the majority of revenue. The Company functions as a digital asset treasury, mainly holding Ethereum (ETH) and exploring opportunities in the tokenization of real-world assets, leveraging ETH as the foundation for digital finance, stablecoins, DeFi, and tokenized assets. The Merchant Banking segment offers strategic, administrative, and regulatory support to newly formed SPACs through the Company's SPAC platform.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: